Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
35
PTGX Quote, Financials, Valuation and Earnings
Last price:
$81.51
Seasonality move
:
6.39%
Day range:
$81.56 - $84.72
52-week range:
$33.70 - $96.54
Dividend yield:
0%
P/E ratio:
129.37x
P/S ratio:
25.13x
P/B ratio:
7.94x
Volume:
352.5K
Avg. volume:
800.7K
1-year change:
118.95%
Market cap:
$5.1B
Revenue:
$434.4M
EPS (TTM):
$0.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
|
$14.9M | -$0.54 | -23.52% | -191.66% | $101.92 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
GKOS
Glaukos Corp.
|
$137M | -$0.20 | 23.76% | -39.64% | $132.71 |
|
JNJ
Johnson & Johnson
|
$24.1B | $2.46 | 7.79% | -40.82% | $231.25 |
|
KRYS
Krystal Biotech, Inc.
|
$105.3M | $1.61 | 31.59% | 41.28% | $289.10 |
|
TMDX
TransMedics Group, Inc.
|
$155.3M | $0.37 | 17.75% | -1.53% | $144.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
|
$81.93 | $101.92 | $5.1B | 129.37x | $0.00 | 0% | 25.13x |
|
ADMA
ADMA Biologics, Inc.
|
$15.59 | $25.67 | $3.7B | 18.31x | $0.00 | 0% | 7.85x |
|
GKOS
Glaukos Corp.
|
$106.74 | $132.71 | $6.1B | -- | $0.00 | 0% | 12.88x |
|
JNJ
Johnson & Johnson
|
$244.55 | $231.25 | $589.2B | 22.14x | $1.30 | 2.1% | 6.30x |
|
KRYS
Krystal Biotech, Inc.
|
$270.26 | $289.10 | $7.8B | 40.54x | $0.00 | 0% | 21.61x |
|
TMDX
TransMedics Group, Inc.
|
$128.52 | $144.20 | $4.4B | 51.91x | $0.00 | 0% | 8.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.620 | 0.26% | 12.83x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
GKOS
Glaukos Corp.
|
11.94% | 1.541 | 2.23% | 4.35x |
|
JNJ
Johnson & Johnson
|
37.69% | -0.049 | 9.89% | 0.69x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.723 | 0.19% | 9.43x |
|
TMDX
TransMedics Group, Inc.
|
59.39% | 1.795 | 13.56% | 6.86x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
GKOS
Glaukos Corp.
|
$104.7M | -$16.4M | -10.16% | -11.73% | -12.26% | -$11.7M |
|
JNJ
Johnson & Johnson
|
$16.4B | $5.4B | 21.45% | 34.46% | 21.9% | $5.9B |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
TMDX
TransMedics Group, Inc.
|
$84.5M | $23.3M | 11.55% | 33.29% | 16.2% | $61.9M |
Protagonist Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTGX or ADMA?
ADMA Biologics, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 27.14%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About PTGX or ADMA?
Protagonist Therapeutics, Inc. has a consensus price target of $101.92, signalling upside risk potential of 24.4%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 64.64%. Given that ADMA Biologics, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Protagonist Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTGXProtagonist Therapeutics, Inc.8 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is PTGX or ADMA More Risky?
Protagonist Therapeutics, Inc. has a beta of 2.264, which suggesting that the stock is 126.409% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock PTGX or ADMA?
Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTGX or ADMA?
Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 129.37x while ADMA Biologics, Inc.'s PE ratio is 18.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 25.13x versus 7.85x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M ADMAADMA Biologics, Inc.7.85x 18.31x $134.2M $36.4M
-
Which has Higher Returns PTGX or GKOS?
Glaukos Corp. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of -12.16%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Glaukos Corp.'s return on equity of -11.73%.
Company Gross Margin Earnings Per Share Invested Capital PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M GKOSGlaukos Corp.78.41% -$0.28 $873.9M -
What do Analysts Say About PTGX or GKOS?
Protagonist Therapeutics, Inc. has a consensus price target of $101.92, signalling upside risk potential of 24.4%. On the other hand Glaukos Corp. has an analysts' consensus of $132.71 which suggests that it could grow by 24.33%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Protagonist Therapeutics, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings PTGXProtagonist Therapeutics, Inc.8 1 0 GKOSGlaukos Corp.11 0 1 -
Is PTGX or GKOS More Risky?
Protagonist Therapeutics, Inc. has a beta of 2.264, which suggesting that the stock is 126.409% more volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.528%.
-
Which is a Better Dividend Stock PTGX or GKOS?
Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTGX or GKOS?
Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Glaukos Corp. quarterly revenues of $133.5M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Glaukos Corp.'s net income of -$16.2M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 129.37x while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 25.13x versus 12.88x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M GKOSGlaukos Corp.12.88x -- $133.5M -$16.2M
-
Which has Higher Returns PTGX or JNJ?
Johnson & Johnson has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 20.83%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Johnson & Johnson's return on equity of 34.46%.
Company Gross Margin Earnings Per Share Invested Capital PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M JNJJohnson & Johnson66.77% $2.10 $130.9B -
What do Analysts Say About PTGX or JNJ?
Protagonist Therapeutics, Inc. has a consensus price target of $101.92, signalling upside risk potential of 24.4%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.44%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings PTGXProtagonist Therapeutics, Inc.8 1 0 JNJJohnson & Johnson9 10 0 -
Is PTGX or JNJ More Risky?
Protagonist Therapeutics, Inc. has a beta of 2.264, which suggesting that the stock is 126.409% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.
-
Which is a Better Dividend Stock PTGX or JNJ?
Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.1% to investors and pays a quarterly dividend of $1.30 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PTGX or JNJ?
Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Johnson & Johnson's net income of $5.1B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 129.37x while Johnson & Johnson's PE ratio is 22.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 25.13x versus 6.30x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M JNJJohnson & Johnson6.30x 22.14x $24.6B $5.1B
-
Which has Higher Returns PTGX or KRYS?
Krystal Biotech, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 81.15%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About PTGX or KRYS?
Protagonist Therapeutics, Inc. has a consensus price target of $101.92, signalling upside risk potential of 24.4%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $289.10 which suggests that it could grow by 6.97%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Protagonist Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTGXProtagonist Therapeutics, Inc.8 1 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is PTGX or KRYS More Risky?
Protagonist Therapeutics, Inc. has a beta of 2.264, which suggesting that the stock is 126.409% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.
-
Which is a Better Dividend Stock PTGX or KRYS?
Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTGX or KRYS?
Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 129.37x while Krystal Biotech, Inc.'s PE ratio is 40.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 25.13x versus 21.61x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M KRYSKrystal Biotech, Inc.21.61x 40.54x $97.8M $79.4M
-
Which has Higher Returns PTGX or TMDX?
TransMedics Group, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 16.91%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat TransMedics Group, Inc.'s return on equity of 33.29%.
Company Gross Margin Earnings Per Share Invested Capital PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M -
What do Analysts Say About PTGX or TMDX?
Protagonist Therapeutics, Inc. has a consensus price target of $101.92, signalling upside risk potential of 24.4%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $144.20 which suggests that it could grow by 12.2%. Given that Protagonist Therapeutics, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Protagonist Therapeutics, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTGXProtagonist Therapeutics, Inc.8 1 0 TMDXTransMedics Group, Inc.7 3 0 -
Is PTGX or TMDX More Risky?
Protagonist Therapeutics, Inc. has a beta of 2.264, which suggesting that the stock is 126.409% more volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 2.059, suggesting its more volatile than the S&P 500 by 105.878%.
-
Which is a Better Dividend Stock PTGX or TMDX?
Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTGX or TMDX?
Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than TransMedics Group, Inc. quarterly revenues of $143.8M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than TransMedics Group, Inc.'s net income of $24.3M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 129.37x while TransMedics Group, Inc.'s PE ratio is 51.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 25.13x versus 8.87x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M TMDXTransMedics Group, Inc.8.87x 51.91x $143.8M $24.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
